Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner by Mehla, Rajeev et al.
Bryostatin Modulates Latent HIV-1 Infection via PKC and
AMPK Signaling but Inhibits Acute Infection in a
Receptor Independent Manner
Rajeev Mehla
1., Shalmali Bivalkar-Mehla
1., Ruonan Zhang
1, Indhira Handy
1, Helmut Albrecht
2,
Shailendra Giri
3, Prakash Nagarkatti
1, Mitzi Nagarkatti
1, Ashok Chauhan
1*
1Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States of America,
2Department of Medicine, University of South Carolina School of Medicine, Columbia, South Carolina, United States of America, 3Department of Experimental Pathology,
Mayo Clinic, Rochester, Minnesota, United States of America
Abstract
HIV’s ability to establish long-lived latent infection is mainly due to transcriptional silencing in resting memory T
lymphocytes and other non dividing cells including monocytes. Despite an undetectable viral load in patients treated with
potent antiretrovirals, current therapy is unable to purge the virus from these latent reservoirs. In order to broaden the
inhibitory range and effectiveness of current antiretrovirals, the potential of bryostatin was investigated as an HIV inhibitor
and latent activator. Bryostatin revealed antiviral activity against R5- and X4-tropic viruses in receptor independent and
partly via transient decrease in CD4/CXCR4 expression. Further, bryostatin at low nanomolar concentrations robustly
reactivated latent viral infection in monocytic and lymphocytic cells via activation of Protein Kinase C (PKC) -a and -d,
because PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect. Bryostatin specifically modulated novel
PKC (nPKC) involving stress induced AMP Kinase (AMPK) inasmuch as an inhibitor of AMPK, compound C partially ablated
the viral reactivation effect. Above all, bryostatin was non-toxic in vitro and was unable to provoke T-cell activation. The dual
role of bryostatin on HIV life cycle may be a beneficial adjunct to the treatment of HIV especially by purging latent virus
from different cellular reservoirs such as brain and lymphoid organs.
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Introduction
Introduction of highly active antiretroviral treatment (HAART)
is able to successfully control HIV viremia in most AIDS patients
and has remarkably reduced the incidence of HIV-associated
neurological complications [1]. While an undetectable viral load is
achieved in most HAART treated patients; latent viral reservoirs
continue to harbor HIV proviral DNA permanently in resting
memory CD4
+ T cells [2–7]. There are several mechanisms
proposed for HIV latency including cellular factors acting as
restriction factors, RNA interference, integration of the proviral
DNA in transcriptionally dormant site that may be derived from
methylation status, Tat activated elongation factor (P-TEFb),
histone modifications or unavailability of cellular transcription
factors like NF-kB that act as co-activators of the HIV LTR [8].
HIV post integration latency is mainly due to transcriptional
silencing that involves chromatin reorganization.
Current antiretroviral therapy lacks a component capable of
reactivating latent viral infection. This latent viral reactivation
component is essential along with HAART to purge the virus from
compartmentalized latent viral reservoirs. Latent HIV responds to
T-cell activation signals [9–15]. T-cell activation strategies include
treatment with proinflammatory cytokines suchas IL-6, TNF-a, IL-
2, and in monocyte/macrophages IFN-c. However, these combi-
nations lead to T-cell depletion and rebound in viral load when
HAART is withdrawn. Moreover, IL-7 also reactivates latent HIV
infection; however, it contributes to maintain latent reservoir in
patientswithlowCD4
+cellcounts[7,16–19].Overall,therelevance
of such immune activation strategies is not considered promising
and T-cell and TCR stimulation was found to be associated with
significant toxicity. New evidence has shown the existence of other
latent reservoirs such as CD14
+CD16
+ monocyte phenotype and
hematopoietic stem cells in the bone marrow [20–23]. Among HIV
patients, monocytic cells are known to undergo latent infection and
are refractory to HIV inhibitors. Macrophages have also been
proposed to harbor latent virus. As a proof of principle, in SIV
infected macaques, CD34
+ CD4
+ monocyte progenitor cells were
shown to be infected early in infection and harbor latent infection
[24], similar to HIV infected patients [25]. Above all, several recent
studies have revealed that patients on HAART support the
existence of other stable viral reservoirs in addition to latently
infected resting memory CD4
+ T cells [26–29].
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genome structure and transcriptional activity. HDAC inhibitors
(Trichostatin A [TSA], valproic acid [VPA], sodium butyrate,
suberoylanilide hydroxamic acid [SAHA]) and the PKC activators
(VPA, PMA and prostratin) have been investigated for their broad
spectrum latent viral reactivation in T-lymphocytes and monocyte/
macrophages. A family of serine/threonine kinase isoenzymes
‘PKCs’ is activated normally by external stimuli on the plasma
membrane receptors coupled to phospholipase C. Once activated,
PKCs exert a variety of effects by phosphorylating their downstream
substrates. Depending on cell type, these include receptor desensi-
tization, cell proliferation and apoptosis. DNA topoisomerase II is
one of the substrates for PKC and inhibition of PKCs lead to
reduced levels of phosphorylated DNA topoisomerase II, thus
leading to inhibition of HIV infection [30]. PKC signaling
reactivates latent HIV infection involving several activated factors
such as NF-kB, NF-AT and AP1. The most attractive PKC agonists
are non mutagenic, non tumorigenic prostratin and SAHA, which
reactivate latent HIV in lymphoid and myeloid cells despite minimal
immune activation and perturbation of cell cycle progression.
Although introduction of valproic acid and SAHA (Vorinostat) were
envisioned to flush out the latent virus from these reservoirs within
few years, valproic acid with HAART failed to deplete latent HIV
reservoir [31–34]. Despite HDAC inhibitors advantages and clinical
approval for cancer and epilepsy, they inhibit general gene
transcription and in particular alter the gene expression in
transformed cells [35,36]. However, SAHA did not induce cell
surface activation markers on bystander T-cells [37]. Although
SAHA was more potent than valproic acid, the induced side effects
such as diarrhea, fatigue, nausea, anorexia and dehydration will
likely render it non-suitable for long term use [38,39].
Bryostatin-1 which is a member of the group of bryostatins, is a
macrocyclic lactone, isolated from a marine bryozoan Bugula
neritina [40] produced by its endosymbiont c-proteobacterial
Endobugula sertula [41]. Bryostatins are known for their anti-
neoplastic activity and PKC activation. Bryostatin also causes
dephosphorylation of CDK2 which inhibits RNA polymerase-II
phosphorylation [42], thus impairing HIV Tat function [43].
Bryostatin-5 has been reported to block stromal cell derived factor-
1 (SDF-1), a natural ligand of CXCR4 receptors [9].
We therefore,sought toinvestigate thepotentialofbryostatin-1in
viral reactivation using latently HIV-infected monocytic as well as
lymphocytic infection models. We also investigated the anti-HIV
activity of bryostatin in acute infection models of X4- and R5-tropic
viruses on Jurkat and Magi cells as well as the mechanism of
bryostatin mediated regulation of latent HIV-infection.
Results
Bryostatin Inhibits HIV-1 Infection in Lymphocytes
Because bryostatin has been shown to down regulate CD3 and
CD4 receptors on T-cells [46], we investigated whether bryostatin
could confer anti-HIV activity against X4- and R5-tropic strains.
Initially, bryostatin was investigated for any adverse effects on
Jurkat and Magi cells (CD4
+/CCR5
+) in a dose response manner.
Bryostatin failed to invoke cytotoxic response even at high doses as
shown in cell survival assay (Fig. 1). In order to study the effect of
bryostatin in acute infection and address whether bryostatin can
enhance or suppress HIV replication, before going directly to
latent viral reactivation studies we performed HIV infection
studies on Jurkat and Magi cells in the presence of variable
concentrations of bryostatin. Interestingly, bryostatin treatment of
acutely HIV-infected cultures demonstrated mild anti-HIV
activity in a dose dependent manner against both R5- and X4-
tropic viruses compared to the untreated infected control on 3
rd
and 5
th day post infection (Figs. 2, 3), albeit, there was no
complete suppression of HIV infection compared to AZT which
was used as a positive control (Fig. 2A). There was an
upregulation of viral p24 in bryostatin treated HIV-infected
cultures similar to untreated infected cultures on the 3
rd day post
infection (pi), however, on the 5
th day pi, p24 levels declined
markedly compared to untreated virus control (Fig. 3D).
Simvastatin was used as a control and failed to reduce p24
expression in acute HIV infected cultures, however revealed some
anti HIV activity when monitored by GFP expression probably
due to less sensitivity of GFP. In our earlier studies, Simvastatin
has manifested week anti HIV activity [45]. Overall, bryostatin
curtailed active viral replication in Jurkat (X4) and Magi cells (R5)
as revealed by percent decrease in GFP positive cells (Fig. 2, 3)
which was validated by p24 antigen in the infected culture
supernatants. To dissect the mechanism of HIV inhibition by
bryostatin, we profiled the expression levels of CD4- and CXCR4-
receptors on Jurkat cells after bryostatin treatment. Interestingly,
bryostatin treatment at 25 ng/ml concentration down-regulated
the expression profile of both CD4- and CXCR4-receptors when
monitored by flowcytometry (Fig. 4A). Following time course
treatment with bryostatin, both the receptors were found to be
transiently down-regulated and returned to baseline levels within
48 h (Fig. 4B), consistent with earlier findings [46,47]. Thus, these
observations suggested the occurrence of another mechanism of
bryostatin mediated HIV inhibition. In order to investigate
whether bryostatin mediated HIV inhibition is independent of
cellular receptors, we employed vesicular stomatits virus envelope
(VSV-G) to pseudotype HIV NLENY1 (VSV-HIV) virus, wherein
VSV-HIV (GFP expressing virus) enters the cells independent of
CD4, CXCR4 and CCR5 receptors. Bryostatin treatment
moderately inhibited VSV-HIV infection independent of receptors
in Hela cells as revealed by decrease in virus productivity and virus
infectivity in TZM-bl cells (Fig. 5A–G). Bryostatin showed similar
results on Hela cells in a single round infection against envelope
deficient HIV-1 NLR+E- strain pseudotyped with VSV-G
envelope (Fig. 5H, I), albeit revealed HIV inhibitory activity of
bryostatin in low nanomolar concentrations such as 25 ng/ml
(27.6 nM), suggesting the occurrence of additional effects on HIV
replication. All together, these data suggested that bryostatin can
abrogate the HIV infection in a receptor independent manner.
Bryostatin modulates HIV Latency via PKC Signaling
HIV-latent reservoirs are established in T-cells and monocyte/
macrophages in the body and maintain the infection for the entire
life of the individual. Bryostatin is a known modulator of PKC
isoforms [48] which are known to have the potential to reactivate
latent HIV infection. Hence, we sought to investigate whether
bryostatin can reactivate latent HIV-infection in monocytic cells.
THP-p89 cells were established by infection with recombinant
HIV-p89-GFP virus (dual tropic) and latent cells were negatively
selected by FACS and verified by treatment with either TNF-a
(10 ng/ml) or TSA (100–300 nM). Following treatment with
bryostatin, latently HIV-infected THP-P89 cells were profoundly
reactivated with evidence of GFP expression within 24 h compared
to negative control (Fig. 6A, B). In parallel, TNF-a was used as a
positive control and DMSO (vehicle) as negative control. Bryostatin
mediated GFP expression in reactivated THP-p89 cells was
confirmed by an authentic viral replication marker p24 in the
supernatants at 24 and 48 h (Fig. 6C). Bryostatin reactivated latent
HIV-1 infection in monocytic cells more robustly than PMA and
TNF-a (Fig. 6C). To corroborate the reactivation of latently HIV-
infected monocytic cells, latently HIV-infected lymphocytic J1.1
Latent HIV Reactivation
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undergoes latent infection phase in memory T-cells, lymphocytic
J1.1 is an ideal in-vitro cell model to study regulation of HIV.
Bryostatin, similar to THP-p89 cells provoked viral reactivation in
latently HIV-infected J1.1 T cells (Fig. 6D). In parallel with
bryostatin, PMA and TNF-a were used as positive controls in viral
reactivation while DMSO (vehicle) was the negative control. Again,
bryostatin showed higher reactivation than TNF-a but slightly
lower than PMA. Recently, prostratin and SAHA were shown to be
potentialcandidates forreactivationoflatentHIVinclinicalsettings
[37,49,50]. Thus, we sought to investigate the latent viral
reactivation strength of bryostatin in comparison to prostratin and
SAHA. Remarkably, bryostatin reactivated latent viral infection
1000-fold more potently than prostratin (phorbol ester) and SAHA
(Fig. 6E, F). Further, we investigated whether latent HIV-
reactivation by bryostatin was a direct effect on LTR-transactiva-
tion in the absence of Tat. We have established a Tat-regulated
GFP-reporter system in SVGA cells and this was used in our
experiments. Following treatment of SVGA-LTR-GFP reporter
cells [14], bryostatin alone failed to transactivate HIV LTR
compared to Tat-expression vector that was used as a positive
control (Fig. 6F). Furthermore, to investigate any synergism
between Tat and bryostatin, we transfected SVGA-LTR-GFP cells
with a suboptimal concentration of a Tat expression vector either
aloneorincombination with bryostatin.Followingtransfectionwith
wild type Tat or mutant Tat expression vector, we monitored HIV
LTR activity by quantifying the number of GFP-positive cells using
flowcytometry. Although, bryostatin in combination with Tat
revealed a slight increase in GFP (Fig. 6G and H), this was
statistically not significant (Fig. 6G). Hence, we inferred that
bryostatin induced HIV-reactivation does not involve direct
transactivation of HIV-LTR either alone or in combination with
Tat.
Bryostatin Mediates Reactivation of Latent HIV via
Classical and Novel PKCs
Bryostatin is a known potent activator of PKC that is active at
low nanomolar concentrations. In addition, PKCs have also been
Figure 1. Bryostatin is non-toxic at its active concentration either alone or in combination with other anti-HIV compounds. Magi and
Jurkat cells were treated with various therapeutic drugs (MF-Metformin (1 mM), Min-Minocycline (5 mg/ml and 10 mg/ml), Sim-Simvastatin (2.5 mM),
and AZT (100 mM), S.Sali-Sodium salicylate (1 mM) either alone or in combination with bryostatin for 48 and 72 h and cell survival was determined
using WST8/CCK8 cytotoxicity assay. (A) Survival of Magi cells after treatment with bryostatin and other drugs, (B) bryostatin in combination with
other drugs. (C) Jurkat cell survival after treatment with bryostatin (25 ng/ml) and other drugs, (D) bryostatin in combination with other drugs. Each
treatment was done in triplicate. (n=2).
doi:10.1371/journal.pone.0011160.g001
Latent HIV Reactivation
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investigate whether bryostatin could reactivate latent HIV
infection via modulating PKCs and identify which specific PKC
isoform is involved in the activation loop. To dissect the HIV
reactivation pathway, we inducted PKCs inhibitors along with
bryostatin on latently HIV infected THP-p89 cells. Pretreatment
with a broad spectrum PKC inhibitor, H7 dihydrochloride,
completely annihilated bryostatin induced reactivation of latent
HIV (Fig. 7A, B). Further, pretreatment with classical PKC
(PKC-a, b1, b2, c) inhibitor GF109203X at less than 0.5 mM
concentration, followed by treatment with bryostatin, was not able
to abrogate the effect of bryostatin on THP-p89 cells. However,
higher concentrations of GF109203X (5 mM) inhibits other PKC
isoforms non-specifically and therefore, attenuated HIV-reactiva-
tion (Fig. 7C and D). In further experiments, a novel PKC
inhibitor, rottlerin (inhibitor of PKC-d, h at IC50 of 3-6 mM) was
able to ablate the bryostatin induced HIV-reactivation in a dose
dependent manner, thus implicating PKC-d and/or h (Fig. 7C,
D). Further, degradation of PKC is dependent on its kinase
activity and activation of PKCs triggers its own degradation via
the ubiquitin-proteasome pathway [52,53]. Hence, we measured
the total PKC levels using western blot in order to investigate
whether bryostatin treatment could modulate degradation of these
isoforms. Following treatment with bryostatin, time dependent
depletion of total PKC-d and PKC-a that is an indicator of PKC
activation, was observed in THP-p89 cells (Fig. 7E–G) whereas
other PKC isoforms were unchanged (data not shown). Hence, on
the basis of PKC activation and inhibition studies, we concluded
that novel PKC isoform, PKC-d is involved in the reactivation of
HIV.
Bryostatin Mediated-HIV-Reactivation Involves Activation
of PKCs via AMPK
AMP-activated protein kinases (AMPK) are known to be
involved in energy homeostasis by regulating the lipid biosynthetic
pathway. AMPKs are activated by an elevated AMP/ATP ratio in
response to various cellular and environmental stresses [54].
Antidiabetic drugs such as metformin and AICAR have been
shown to upregulate AMPK, which play a significant role in PKC
activation [55,56]. In order to implicate the AMPK pathway in
Figure 2. Bryostatin ablates R5-tropic HIV infection. Magi cells (CD4
+/CCR5
+) were infected with 100 ng/ml p24 equivalent HIV recombinant
NLENYU2 virus expressing YFP. (A) Productive viral infection was monitored semi-quantitatively on 3rd and 5th dpi. (B) GFP-positive cells per 10 fields
were counted in HIV-infected cultures and plotted as mean. (C) Dose dependent anti-HIV effect of bryostatin was monitored by p24 assay. (D) p24
levels in the culture supernatants after treatment with bryostatin (25 ng/ml) and other compounds on 3rd and 5th day post infection are shown.
Sodium salicylate (1 mM) was used as a negative control in each set of experiments. Degree of significance for bryostatin treatment was relative to
virus control, * p,0.05, # p,0.001. (n=4).
doi:10.1371/journal.pone.0011160.g002
Latent HIV Reactivation
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an AMP competitive inhibitor, compound-C that blocks the AMP
binding c subunit of AMPK. Compound-C treatment moderately
ablated the bryostatin or PMA-mediated latent reactivation but
not by metformin/AICAR (AMPK activators), suggesting the
involvement of AMPK in part (Fig. 8A, B). AMPKs are highly
conserved heterotrimeric protein complexes containing a catalytic
a subunit and b/c subunits involved in target and regulatory
functions. We further investigated the activation and expression
levels of both a and b subunits of AMPK in bryostatin treated
THP-p89 cells. Bryostatin increased phosphorylation levels of the
regulatory b1 subunit at serine-108 residue within 10 min of
treatment (Fig. 8C, 8D). Furthermore, phosphorylation of this
subunit was accompanied by phosphorylation at threonine 172
catalytic AMPK a subunit that was sustained at basal levels
(Fig. 8C, D).
Remarkably, pretreatment of latent HIV-infected monocytic
cells with nPKC inhibitor rottlerin followed by AMPK activators
metformin or AICAR treatment, abrogated the bryostatin
mediated HIV-reactivation (Fig. 9A, B). This infers that PKCs
are the main effector kinases downstream of AMPK. Moreover,
using Bryostatin or PMA as a positive control for PKC activation,
there was a decrease in the phosphorylation levels of the beta
subunit of AMPK compared to the vehicle control as shown
earlier (Fig. 8C and D). The involvement of AMPK via PKC
isoforms was investigated by protein profiling using Western
blotting. Treatment of THP-p89 cells either with PMA or
Bryostatin led to the activation of PKC-a and PKC-d and were
flagged for degradation compared to cell and vehicle controls
(Fig. 9C). However, compound-C mediated inhibition of AMPK
rescued the PKC degradation within 24 h. Although, induction of
AMPK by metformin had no effect on the PKCs, it seems that the
AMPK was already activated at basal activation state in these cells
(Fig. 9C). Thus, activated AMPK (metformin or AICAR)
regulates HIV reactivation in a PKC dependent manner.
Bryostatin Synergizes Tat-Mediated LTR-Transactivation
via Nef
PKCs (novel) are known to mediate the subcellular localization
of Nef and phosphorylation of Nef protein in the N-terminal
region at arginine 6, resulting in activation of HIV-transcription
using suboptimal concentrations of Tat [57,58]. Hence, to have a
Figure 3. Bryostatin ablates X4-tropic HIV infection. Jurkat cells were pretreated either with bryostatin or other drugs, infected with 50 ng/ml
p24 equivalent recombinant NLENY HIV-1 expressing YFP followed by continuation in respective treatments. (A) YFP expression levels were
monitored semi-quantitatively (data shown in representative pictures on 5th dpi). (B) Bryostatin treatment ablated HIV infection as demonstrated by
decrease in YFP-positive Jurkat cells on 5th dpi. (C) Productive HIV replication was monitored by YFP-positive cells on 5th dpi and (D) validated by
p24 levels in infected culture supernatants on 3rd and 5th dpi. Results were statistically significant (#p,0.005, * p,0.0001) compared to HIV-1
NLENY virus control. (n=3).
doi:10.1371/journal.pone.0011160.g003
Latent HIV Reactivation
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facilitate HIV transcription via Nef protein. To validate this
hypothesis, we performed co-transfection experiments using
suboptimal concentrations of Tat expression vector (2 ng) with
increasing concentrations of Nef expression construct (0 to 100 ng)
on LTR-GFP reporter (SVGA-LTR-GFP) cells. Neither Nef nor
bryostatin alone conferred any additional effect on Tat-mediated
HIV LTR-transactivation (Fig. 10A). However, bryostatin
treatment after co-transfection of wild type Tat but not mutant
Tat (negative control) with Nef moderately potentiated LTR-
transactivation in SVGA-LTR-GFP cells (Fig. 10B), suggesting
that bryostatin could synergize with Nef and Tat in transcription.
Although, there was a moderate increase in the number of GFP-
positive cells by bryostatin and Nef, there was no increase in the
mean fluorescence intensity (Fig. 10C).
Bryostatin Induces PKC Activation without T-Cell
Activation
Current therapeutic agents employed in viral reactivation
require micro molar concentrations and have limited reactivation
efficacy. In vivo latent viral reactivators have shown poor
performance in clinical trials and even in combination with other
activators were found to be ineffective in complete depletion of
viral reservoirs [50]. Besides, the major disadvantage of these
therapeutic agents in-vitro is their propensity to non-specifically
activate bystander T-cells. We therefore, investigated the T-cell
activation potential of bryostatin on primary human lymphocytes
using CD25 and CD69 as activation markers. Human CD4-Tcells
were cultured in T25 flasks. After three days in culture, they were
treated with PHA and IL-2, and T-cell activation was monitored
by flow cytometry using antibodies against CD25 and CD69. In
parallel, we performed T-cell activation studies with traditional
agents used in latent HIV-reactivation. Bryostatin at its active
concentration (25 ng/ml) failed to activate T-cells compared to
SAHA and prostratin. Lymphocytes stimulated with PHA and IL-
2 were used as a positive control (Fig. 11). These observations
demonstrate that bryostatin is a novel compound for HIV
reactivation without inducing normal T-cell activation compared
to SAHA and prostratin.
Discussion
Despite the suppression of detectable plasma viremia in HIV
infected patients; roughly one in a million CD4+ T cells will
establish a latently infected long lived cell population [59]. Several
broad spectrum therapeutic molecules are being investigated as
potential candidates to eliminate latent HIV-reservoirs. Various
strategies such as T-cell activation including IL-7, [16,17],
Amphotericin B [60], PKC activating phorbol ester derivatives
such as prostratin and plant derived products like Jatrophane
diterpene SJ23B [61,62] and histone deacetylase (HDAC)
inhibitors such as SAHA and Valproic acid [36,37,63] and 5HN
(via oxidative stress and NF-kB independent pathway) [7] have
been shown to reactivate latent HIV-1 infection. However, none
of these strategies provided sufficient reactivation to be considered
viable candidates for clinical purposes.
Our investigations on phorbol ester derivative bryostatin-1
revealed mild inhibitory effect on X4 and R5 acute HIV infections
(Fig. 2, 3). Similarly, X4-tropic anti-HIV activity was consistent
with earlier study results [47]. The inhibition was in part, due to
down-regulation of CD4 and CXCR4 in lymphocytes as well as
receptor independent (Fig. 4, 5). Although, receptors started
reappearing between 6–24 h of treatment, sustained attenuation of
viral replication in our observations suggested that bryostatin was
conferring antiviral activity through some other mechanism as well
(Fig. 4). Intriguingly, it is possible bryostatin may mediate this
effect by regulating innate defense system in cells and require
further investigations. Bryostatin induces PKCs which are in fact
responsible for a wide range of activities including cellular
Figure 4. Bryostatin down-regulates CD4 and CXCR4 receptor expression on Jurkat cells. (A) Jurkat cells were treated either with
bryostatin (25 nM) or left untreated for 0 to 48 h followed by immunostaining with fluorescently labeled anti-CD4 and anti-CXCR4 antibodies and
monitored by flowcytometry. Representative dot plots at 3 h and 48 h of bryostatin treatment, isotype control and vehicle control (DMSO). (B) Time
course of expression profile of CD4
+/CXCR4
+ receptors on Jurkat cells upon treatment with bryostatin (n=2).
doi:10.1371/journal.pone.0011160.g004
Latent HIV Reactivation
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tumorigenic phorbol ester, isolated from the Samoan medicinal
plant, Homalanthus nutans, prostratin has been reported to
activate NF-kB via novel PKC isoforms [49], thus providing a
rationale to be included in a HIV therapeutic intervention
regimen. We therefore, compared the activation potential of these
two signal transducers and demonstrated that bryostatin was
potently active in reactivation of latently HIV infected cells at
much lower concentrations than prostratin (Fig. 6A–F). Recently,
Lint and coworkers [50] reported that co-administration of
prostratin with HDAC inhibitors such as sodium butyrate,
apicidin; MS-275 and scriptaid would synergistically reactivate
latent HIV infection, suggesting their therapeutic potential.
However, prostratin in further studies was proved to be toxic at
its effective concentration [49]. Interestingly, bryostatin at its
effective concentrations failed to activate primary human lympho-
cytes (PBMCs) (Fig. 11) and was extremely potent in reactivation
of latent HIV-1 compared to prostratin and SAHA (Fig. 6A–F).
Approaches for activating gene expression in latently infected
cells rely on either stimuli that activate resting T cells or Tat [65].
In the current study, bryostatin in the absence of Tat neither
showed a direct effect nor any synergy with Tat protein on HIV
LTR (Fig. 6G–H), but revealed that PKC isoenzymes were
involved in the bryostatin-mediated latent HIV reactivation
(Fig. 7A, B). PKC isoenzymes are classified into three subfamilies
as conventional or classical (a,b1, b2, c), novel (d, e, g, h) and
atypical (f, l) depending on the subcellular localization,
biochemical properties and substrate specificity [66]. We attempt-
ed to decipher which of the isoenzymes are involved in the latent
HIV reactivation process. Using GF109203X and rottlerin,
inhibitors of classical and novel isoenzymes, we found that novel
PKCs were intimately involved in latent HIV reactivation process
(Fig. 7). Among nPKCs, PKC-h has been exclusively found in T
cells and its role in TCR signal transduction is well established [64]
whereas PKC-d is ubiquitously expressed, therefore, its role in
viral activation was expected.
Figure 5. Bryostatin inhibits HIV-1 independent of viral receptors. (A and B) Hela cells were pretreated with bryostatin (27 nM), vehicle, and
AZT as positive control and thereafter infected with VSV pseudotyped-NLENY1 HIV. Productive HIV replication was monitored using YFP expression
after 3dpi. Results were significant at p,0.05 (C) Virus production was further confirmed by p24 levels in infected culture supernatants by
quantitative ELISA. (D) Schematic representation of the experimental design of virus infection in HeLa cells and infectivity assay in TZM-bl cells is
shown. (E and F) Virus infectivity in the bryostatin treated HIV-infected culture supernatants was monitored by infecting TZM-bl cells either with YFP
expression as a marker or (G) viral p24 production after 3dpi. (H and I) Schematic representation of single round infection experiment, bryostatin
mediated HIV inhibition was monitored by p24 assay in a single round infection on Hela cells using VSV pseudotyped HIV-NLR+E- (*p,0.05,
#p,0.005) (n=2).
doi:10.1371/journal.pone.0011160.g005
Latent HIV Reactivation
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binding to signal lipids and translocation from cytosol to the
membrane [67]. After activation, the levels decline upon
translocation to endosomes followed by ubiquitination leading to
proteasomal degradation thus producing a brief pulse of PKC
activity in response to stimulus [52,53]. Rapid degradation of
diacylglycerol further shortens the duration of PKC activation.
Similarly, in our study, treatment with bryostatin or PMA led to
activation that resulted in reduced levels of PKC-a and PKC-d
(Fig. 7).
During HIV reactivation, target cells get stressed leading to loss
of energy. AMPKs are known to act mainly as a central switch
point in energy regulation; however, their role in response to
cellular stress or infection has not yet been elucidated. Moreover,
accumulated evidence has suggested that AMPKs not only
regulate metabolism of fatty acids and glycogen but are also
involved in other cellular processes such as modulating EF2 and
TSC2/mTOR pathways [68] including NF-kB activation [69].
Our observations suggest that although AMPKs themselves were
not directly involved in viral reactivation (via metformin or
AICAR), however, activated AMPKs were found to coordinate the
process via PKC. This was demonstrated upon pretreatment with
AMPK inhibitor compound-C that resulted in attenuation of
either bryostatin- or PMA-induced HIV-reactivation in monocytic
cells (Fig. 8). In addition, metformin or AICAR activated AMPK
coordination in bryostatin mediated latent HIV reactivation which
was abolished by novel PKCs inhibitor Rottlerin (Fig. 9). These
observations inferred that novel PKCs are the key regulatory
molecules which are coordinated through AMPKs. Further, we
also observed a small but significant synergistic transactivation
effect of bryostatin along with Nef and suboptimal concentrations
of Tat (Fig. 10). PKCs (novel) are known to phosphorylate the N-
terminal of Nef protein which in turn will increase HIV
transcription [57] and might be the phenomenon occurring upon
bryostatin treatment in our experiments.
The dual action of bryostatin inhibiting acute HIV-1 infection as
well as reactivation of latent HIV via novel PKC pathway without
T-cell activation and cytotoxicity makes it a promising novel
therapeutic agent along with HAART to purge latent virus from
tissue reservoirs (Fig-12). Future challenges will include the
Figure 6. Bryostatin reactivates latent HIV infection in monocytic cells. (A) THP-p89 cells were treated with bryostatin (25 ng/ml) for
different durations and fluorescence was quantified by flowcytometry. (B) GFP expression was directly proportional to the level of activation in these
cells as visualized by fluorescence microscopy. Quantification of GFP fluorescence in bryostatin-treated latently-infected THP-p89 cells was done by
flowcytometry. (C) Bryostatin primed viral reactivation at 24 and 48 h, was followed by release of viral p24 in culture supernatants using ELISA. (D)
Bryostatin induced viral reactivation was further confirmed on another latently HIV-infected lymphocytic cell model (J1.1), 48 h post treatment using
viral p24 as a marker. (E and F) Comparative dose response of bryostatin, prostratin and SAHA, for viral reactivation in THP-p89 cells. Bryostatin at a
1000 fold lower concentration, EC50,0.25 nM reactivated latent HIV in THP-p89 cells more potently than SAHA and prostratin (# p,0.001,
*p ,0.005). (G and H) Bryostatin in absence of Tat failed to activate HIV promoter. SVGA-LTR-GFP cells were either treated with bryostatin, vehicle
control or transfected with wild type Tat-expression vector (positive control) in parallel with control mutant-Tat expression vector (negative control).
The LTR transactivation was measured after 48 h by GFP fluorescence. Nuclei were stained with Hoechst 33342. (G) GFP expression visualized by
fluorescence microscopy; pictures and bar graph are showing level of fluorescence. (H) Dose response for Tat-expression vector with or without
bryostatin (25 ng/ml) in SVGA-LTR-GFP cells (n=3).
doi:10.1371/journal.pone.0011160.g006
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therapeutic behavior of bryostatin in combination with other drugs.
Materials and Methods
Chemicals and Reagents
Bryostatin-1 and prostratin were purchased from BioMol
Research Laboratories, Inc. (PA, USA). SAHA was purchased
from Cayman chemicals (MI, USA). GF109203X (Bisindolylma-
leimide-1), rottlerin and H7 dihydrochloride were purchased from
Calbiochem (CA, USA). Compound-C and 5-Aminoimidazole-4-
carboxamide ribonucleoside (AICAR) were purchased from
Toronto Research Chemicals, Inc. (ON, Canada). All other
chemicals were purchased from Sigma Chemical Co. (MO, USA).
The stock solutions of rottlerin (10 mM), H7 dihydrochloride and
bryostatin (25 ng/ml) were prepared in dimethylsulfoxide
(DMSO), and GF109203X (5 mM) was prepared in 50% DMSO
in distilled water. AICAR (100 mM), metformin (100 mM),
minocycline (10 mM), AZT (10 mM) and sodium salicylate
(100 mM) were prepared in PBS followed by filter sterilization
and aliquoted for one time use and stored at 220uC until used.
Human anti-CD4, CXCR4, CD25, CD69 antibodies were
purchased from BD-Biosciences (CA, USA). Anti-PKC isotype,
phospho- and total-AMPK antibodies were purchased from Cell
Signaling (MA, USA), anti-b actin antibody was purchased from
Sigma, anti-rabbit-HRP and anti-mouse-HRP conjugate antibod-
ies were purchased from Bio-Rad (CA, USA).
Cell Culture and Latently HIV-Infected Cells
All cell culture (primary human and cell lines), HIV infection
and proviral HIV DNA studies were performed according to
university guidelines in a biocontainment facility approved by
institutional biosafty committee (IBC) of the University of South
Carolina. Peripheral blood mononuclear cells (PBMCs) were
obtained from New York Blood Bank, Jurkat and J1.1 cells were
from AIDS Research and Reference Reagent Program, NIH, and
latently HIV-infected monocytic cell line THP-p89 [12] were
maintained in RPMI (Gibco BRL life technologies, Inc., NY,
USA) supplemented with 10% fetal bovine serum (FBS). HeLa,
Magi (CD4/CCR5), TZM-bl cells (CD4/CXCR4/CCR5) were
obtained through AIDS Research and Reference Reagent
Program, NIH, and SVGA-LTR-GFP reporter cells [14], were
maintained in DMEM containing 10% FBS. PBMCs were
separated from normal human blood obtained through New York
blood bank (NY, USA,) and cultured in RPMI-1640 containing
15% FBS. Monocytes were depleted by selective adherence to the
plastic surface in culture plate and floating cells were cultured as
lymphocytes [44]. Subsequently lymphocytes were stimulated with
1% PHA (Invitrogen Co., CA, USA) and 1 mg/ml IL-2 (R&D
Systems, Inc., MN, USA).
Cytotoxicity Assay
Cell Counting Kit-8 (CCK-8) (Dojindo Molecular technologies,
Inc., MD, USA) was used in cell survival assays. CCK-8 utilizes
Dojindo’s highly water-soluble tetrazolium salt. WST-8 [2-(2-
methoxy-4-nitrophenyl)-3- (4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, monosodium salt] produces a water-soluble
formazan dye upon reduction in the presence of an electron
carrier. WST-8 is reduced by dehydrogenases in cells to give a
yellow colored product (formazan), which is soluble in the tissue
culture medium. The amount of the formazan dye generated by
the activity of dehydrogenases in cells is directly proportional to
the number of living cells. Magi cells were seeded at a density of
2.5610
4 while Jurkat cells were plated at a density of 5.0610
4 per
well in 96 well plate. On the subsequent day and thereafter,
various chemical treatments were given in triplicate in a dose
response manner. After 48 and 72 h, the cell supernatants were
removed and 100 ml PBS and 10 ml CCK-8 reagent was added to
the cells. After 3 h incubation at 37uC, supernatants were collected
and the absorbance was measured at 450 nm wave length on
Figure 7. Bryostatin reactivates latent HIV infection via activation of classical and novel PKCs. (A and B) THP-p89 cells were pretreated
with bryostatin either alone or with broad spectrum PKC inhibitor H7 dihydrochloride or (C and D) different concentrations of classical PKC inhibitor
GF109203X and novel PKC inhibitor Rottlerin as indicated and monitored for GFP fluorescence by flowcytometry. (E) Total PKCa activation at different
time points post-treatment with bryostatin. (F) PKC-d and PKC-a in replicate experiment was degraded in a time dependent manner within 72 h of
treatment with bryostatin. (G) Quantitative profile of PKC-a and d after normalization with beta actin.
doi:10.1371/journal.pone.0011160.g007
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USA). Percentage cell survival was calculated as ODtest–ODcell
control and data were plotted as a mean of three tests and standard
error of mean (SE) using sigma plot v8.0 (SPSS Inc.).
Plasmid and Viral Constructs
HIV NL4-3 proviral-DNA wild type or envelope-deficient,
p89.6 (dual tropic), NLENY1 and NLENYU2 carrying the YFP
gene between the envelope and Nef in NL4-3 proviral DNA was
used [12,13,45]. HIV wild type Tat (101 amino acids [aa]) and
mutant-Tat 47 prepared by deleting 48–101 aa, were cloned at the
BamH1 and EcoR1 sites in pcDNA vector. HIV-LTR was cloned
upstream of GFP gene in CMV-promoter-deleted pEGFP vector
and SVGA-LTR-GFP stable reporter cell line was generated
[12,14]. HIV NL4-3 and NLR
+E
2 proviral DNA, Nef
(pcDNA3.1SF2-Nef) and VSV-G vectors were obtained through
NIH AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, Bethesda, USA.
Viral Packaging and Pseudotyping
HIV NL4-3, HIV-NLENY1 and HIV-NLENYU2 and,
NLR
+E
2 proviral DNA were used for packaging viral particles
in 293T cells using HIV-proviral DNA alone or in combination
with VSV-G expression vector [12]. Briefly, 293T cells were
seeded in 100 mm tissue culture plates (BD Falcon, IL, USA).
After overnight incubation cells were transfected with 17 mgo f
proviral DNA constructs either alone or in combination with
4.0 mg VSV-G expression vector, using Lipofectamine 2000
(Invitrogen). The supernatants were harvested 72 h post transfec-
tion followed by centrifugation at 300 g for 10 min and
subsequent treatment with RNase free DNase-1 (Qiagen, CA,
USA), and titrated for HIV p24 antigen (Zeptometrix Corp,
Buffalo, NY, USA).
HIV Infection
Testing anti-HIV activity of bryostatin and other compounds
against R5-tropic strain, ,1.5610
5 Magi cells (CD4
+/CCR5
+)
Figure 8. AMPK mediate reactivation of latent HIV infection via PKC. (A) GFP-expression in THP-p89 cells upon treatment with 10 mM
Compound-C (CC), an AMPK inhibitor; 1 mM Metformin (MF) and AICAR (AMPK activators) either alone or in combination with bryostatin. Activation
of AMPK alone does not show viral reactivation. (B) Quantification of THP-p89-reactivated GFP-positive cells by flowcytometry. (C) Western blots for
phosphorylated AMPK-alpha subunit after treatment with bryostatin (25 ng/ml) were monitored at different time points. (D) Quantification of
phospho-alpha and -beta subunit bands on western blots. Bryostatin treatment dephosphorylates AMPK-regulatory subunit b in a time dependent
manner.
doi:10.1371/journal.pone.0011160.g008
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TM), while for X4-tropic
HIV NL4-3, ,2.5610
5 Jurkat cells were seeded in 24 well plate.
The next day cells were pre-treated with various chemical reagents
in optiMEM followed by infection with either NLENYU2 (R5) at
100 ng/ml equivalents- or with NLENY (X4) at 50 ng/ml
equivalent -of p24 respectively for 2 h. The infected cells were
washed twice and cultured for several days. The productive HIV
infection was monitored semi-quantitatively by counting GFP-
expressing cells in 10 random fields in each well as well as
quantitatively by p24 ELISA. Appropriate controls were used such
Figure 9. PKCs regulate reactivation of latent HIV infection downstream of AMPK. (A and B) nPKC (novel PKC) inhibitor, rottlerin
abrogated viral reactivation in THP-p89 cells after AMPK activation (metformin and AICAR). Activation of AMPK alone did not affect viral reactivation.
(C) Bryostatin- and PMA-mediated activation of PKC led to complete degradation of PKC-a and PKC-d compared to vehicle control. H7
dihydrochloride and rottlerin (positive controls) mediated inhibition of activation of classical and novel PKCs prevented the degradation of total PKCs.
Metformin an AMPK activator had no effect on the PKC, however, the inhibitor of AMPK, compound-C (inhibits AMPK activation) rescued the PKC
degradation or prevented PKC activation in 24 h.
doi:10.1371/journal.pone.0011160.g009
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while AZT (100 mM) and minocycline (5 mg/ml) were used as
positive controls. For testing receptor-independent HIV inhibition
in single round infection, ,3.5610
5 Hela cells (CD4 –ve) in 12-
well plate were infected either with VSV-NLENY or VSV-
NLR+E- HIV-1 prior to treatment with 25 nM bryostatin and
appropriate controls. Testing HIV-infectivity after bryostatin
treatment, supernatants were collected from HIV infected cultures
treated with bryostatin and used for infection of TZM-bl (CD4
+/
CXCR4
+) cells (,3.5610
5) in 12-well plate. Virus production was
monitored 3 day post infection by monitoring GFP fluorescence
and viral p24 by ELISA.
Flowcytometry
The quantification of reactivated latently HIV infected, acutely
infected or Tat transfected LTR-GFP cells was performed after
fixation with 3% paraformaldehyde for 30 min at 4uC followed by
washing twice with PBS. The effects of bryostatin mediated
re-programming of cell surface receptors on PBMCs or Jurkat cells
were monitored by flowcytometry after staining with fluorescently
labeled anti-human CD4, CD25, CD69, and CXCR4 antibodies
respectively. Bryostatin or SAHA mediated T-cell activation
(PBMCs) was monitored after staining for activation markers with
fluorescently labeled anti-human CD25 and CD69 antibodies.
Briefly, 1610
6 cells were washed with PBS and stained with 20 ml
of fluorescently labeled antibodies in 100 ml PBS containing 1%
FBS for 45 min on ice. Subsequently, cells were washed three
times with PBS and finally resuspended in 1 ml PBS containing
1% FBS and 10,000 cells were acquired using FACScan
flowcytometer with Expo32 v1.1B software (Beckman Coulter,
Inc., FL, USA).
LTR Transactivation and HIV Reactivation
SVGA-LTR-GFP reporter cells were established by stable
transfection using HIV-LTR-GFP expression vector [14], mono-
clonal cells were cloned and used in transactivation studies. The
Figure 10. Bryostatin synergizes Tat- and Nef-mediated LTR-transactivation. SVGA-LTR-GFP reporter cells were transfected with 2 ng Tat-
expression vector (suboptimal dose) and increasing concentrations of Nef-expression vector. (A) Quantification of GFP-positive cells. (B) SVGA-LTR
GFP cells were transfected with 2 ng Tat-expression vector and 100 ng Nef-expression vector in the presence or absence of bryostatin (25 ng/ml)
followed by GFP quantification using flowcytometry. (C) Mean fluorescence intensity (MFI) for the same experiment (B). (n=3).
doi:10.1371/journal.pone.0011160.g010
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with Tat expression vector in a dose responsive manner. A
subsequent treatment with 25 ng/ml bryostatin was given followed
by transfection with either Tat expression vector or mutant-Tat
(defective in its transactivation function), which was used as a
negative control. Each plasmid of 50 ng concentration was
transfected using Lipofectamine 2000 (Invitrogen) as described
earlier [14]. After 48 h of transfection, cells were stained with
1 mg/ml Hoechst-33342 for 15 min at 37uC and the fluorescence
was monitored using a Nikon Eclipse fluorescence microscope.
Results were quantified by either mean GFP florescence
normalized with Hoechst fluorescence on BioTek synergy 2.0
microplate reader or by flowcytometry.
THP monocytic cells, which are latently infected with recombi-
nant HIV p89-GFP [12,15,45], were seeded into 6 well plate at a
density of 7610
5 cells per well. The basal viral activity in THP-p89
cells was barely detectable with complete absence of GFP-expression
and p24. Viral reactivation was performed upon treatment either
with TNF-a or bryostatin. After overnight cell seeding, cells were
treated with TNF-a (positive control), bryostatin (25 ng/ml) or
inhibitorsofPKC isoformsatdifferentconcentrationseitheralone or
in combination with bryostatin, in parallel with appropriate controls.
After 24 h of treatment, cells were fixed with 3% paraformaldehyde
followed by staining with 1 mg/ml of Hoechst 33342 dye for 15 min
at 37uC and quantified by flow cytometry. The percentage of GFP
expressing cells was used as a measure of viral activation/
suppression. Each experiment was done in duplicate and a result
of % GFP was expressed as a mean of two readings.
Western Blotting
Latently HIV-infected THP-p89 cells were seeded in 6 well
plates followed by treatment with 25 ng/ml bryostatin along with
vehicle control (DMSO) and compound-C. After 48 h of
treatment, cells were washed twice with ice cold phosphate
buffered saline (pH 7.2) followed by centrifugation at 450 g for
5 min. Cell pellets were lysed with RIPA buffer (Sigma)
supplemented with protease inhibitor cocktail (Pierce, IL, USA)
on ice for 5 min. Subsequently, cell debris was removed by
centrifugation at 12000 g for 2 min and the protein concentration
was determined by BCA kit (Pierce). The supernatants (25 mg
protein) were analyzed on SDS-PAGE and transferred onto PVDF
membrane (Bio-Rad) followed by blocking with 5% milk (Bio-Rad)
and 0.1% tween-20 in PBS buffer. The blotted membranes were
incubated with appropriate antibodies against PKC or AMPK
(phosphorylated or normal isoforms) and probed with anti-rabbit
HRP conjugated secondary antibody (1:10000). The blots were
developed using ECL reagent (GE healthcare, PA, USA) and
captured on to Kodak BioMax XAR film (Rochester, NY, USA).
The protein bands were normalized to b-actin (1:10000) and were
quantified using ImageJ software (v 1.41; NIH).
Figure 11. Effect of bryostatin on T-cell activation. Human PBMCs depleted of monocytes were cultured for 3 days and either activated with
PHA and IL-2 or treatment with bryostatin for 2 days, followed by immunostaining with fluorescently labeled human anti-CD25 and anti-CD69
antibodies and monitored by flowcytometry. Representative dot plots for PHA and IL-2 activation, isotype control and bryostatin treatment are
shown (n=2).
doi:10.1371/journal.pone.0011160.g011
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Results are represented as mean 6 SE for each bar graph using
Sigma plot v8.0 with associated p values for each treatment group
compared to their respective controls. Statistical analysis was done
using origin 6.1 software. Significance between two groups was
calculated using two tailed student’s t-test followed by one-way
analysis of variance. p,0.05 was considered significant.
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